Current Atherosclerosis Reports

, Volume 2, Issue 2, pp 104–109

Antiplatelet therapy in secondary stroke prevention

  • Bradford B. Worrall
  • Karen C. Johnston

DOI: 10.1007/s11883-000-0103-3

Cite this article as:
Worrall, B.B. & Johnston, K.C. Curr Atheroscler Rep (2000) 2: 104. doi:10.1007/s11883-000-0103-3


This article focuses on recent data about the safety and effectiveness of antiplatelet therapies for secondary stroke prevention. Highlights include a discussion of changes in the professional labeling for aspirin and the results of a low- versus high-dose aspirin trial (Aspirin after Carotid Endarterectomy trial). Safety issues regarding aspirin also are considered. Other topics include a review of recent data on thrombotic thrombocytopenic purpura (TTP) associated with ticlopidine and a brief update on clopidogrel. A summary of discussions related to the European Stroke Prevention Study 2 data and Food and Drug Administration consideration of combination dipyridamole/aspirin therapy are presented.

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Bradford B. Worrall
    • 1
  • Karen C. Johnston
    • 1
  1. 1.Department of NeurologyUniversity of Virginia Health Systems #394CharlottesvilleUSA

Personalised recommendations